Crystal Structure, Stability and Desolvation of the Solvates of Sorafenib Tosylate
Abstract
:1. Introduction
2. Experimental Section
2.1. Materials
2.2. Solvate Screening and Preparation
2.3. Crystal Structure Determination
2.4. Characterization
2.5. Solubility Profile of Solvates in Binary Solvent Mixtures
2.6. Desolvation Behavior of Solvates
3. Results and Discussion
3.1. Solvate Screening
3.2. Crystal Structure of Solvate
3.3. Hirshfeld Surface Analysis
3.4. Characterization
3.5. Solubility of Solvate
3.6. Desolvation of Solvates
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Aitipamula, S.; Chow, P.S.; Tan, R.B.H. Solvates and polymorphic phase transformations of 2-chloro-4-nitrobenzoic acid. CrystEngComm 2011, 13, 1037–1045. [Google Scholar] [CrossRef]
- Fujii, K.; Aoki, M.; Uekusa, H. Solid-state hydration/dehydration of erythromycin A investigated by ab initio powder X-ray diffraction analysis: Stoichiometric and nonstoichiometric dehydrated hydrate. Cryst. Growth Des. 2013, 13, 2060–2066. [Google Scholar] [CrossRef]
- Yuan, L.; Lorenz, H. Solvate formation of bis (demethoxy) curcumin: Screening and characterization. Crystals 2018, 8, 407. [Google Scholar] [CrossRef]
- Bechtloff, B.; Nordhoff, S.; Ulrich, J. Pseudopolymorphs in industrial use. Cryst. Res. Technol. 2001, 36, 1315–1328. [Google Scholar] [CrossRef]
- Li, L.; Du, R.; Du, Y.; Zhang, C.; Guan, S.; Dong, C.; Zhang, L. Febuxostat-minoxidil salt solvates: Crystal structures, characterization, interconversion and solubility performance. Crystals 2018, 8, 85. [Google Scholar] [CrossRef]
- Ferrari, E.S.; Davey, R.J.; Cross, W.I.; Gillon, A.L.; Towler, C.S. Crystallization in polymorphic systems: The solution-mediated transformation of β to α glycine. Cryst. Growth Des. 2003, 3, 53–60. [Google Scholar] [CrossRef]
- Zhao, J.; Wang, M.; Dong, B.; Feng, Q.; Xu, C. Monitoring the polymorphic transformation of imidacloprid using in situ FBRM and PVM. Org. Process Res. Dev. 2013, 17, 375–381. [Google Scholar] [CrossRef]
- Zhu, M.; Wang, Y.; Li, F.; Bao, Y.; Huang, X.; Shi, X.; Hao, H. Theoretical model and experimental investigations on solution-mediated polymorphic transformation of theophylline: From polymorph I to polymorph II. Crystals 2019, 9, 260. [Google Scholar] [CrossRef]
- Bērziņš, A.; Skarbulis, E.; Rekis, T.; Actiņš, A. On the formation of droperidol solvates: Characterization of structure and properties. Cryst. Growth Des. 2014, 14, 2654–2664. [Google Scholar] [CrossRef]
- Chavez, K.J.; Guevara, M.; Rousseau, R.W. Characterization of solvates formed by sodium naproxen and an homologous series of alcohols. Cryst. Growth Des. 2010, 10, 3372–3377. [Google Scholar] [CrossRef]
- Thakuria, R.; Nangia, A. Olanzapinium salts, isostructural solvates, and their physicochemical properties. Cryst. Growth Des. 2013, 13, 3672–3680. [Google Scholar] [CrossRef]
- Perlovich, G.L.; Blokhina, S.V.; Manin, N.G.; Volkova, T.V.; Tkachev, V.V. Polymorphs and solvates of felodipine: Analysis of crystal structures and thermodynamic aspects of sublimation and solubility processes. CrystEngComm 2012, 14, 8577–8588. [Google Scholar] [CrossRef]
- Zhang, Q.; Lu, L.; Dai, W.; Mei, X. Polymorphism and isomorphism of Huperzine A solvates: Structure, properties and form transformation. CrystEngComm 2014, 16, 1919–1926. [Google Scholar] [CrossRef]
- Vangala, V.R.; Chow, P.S.; Tan, R.B.H. The solvates and salt of antibiotic agent, nitrofurantoin: Structural, thermochemical and desolvation studies. CrystEngComm 2013, 15, 878–889. [Google Scholar] [CrossRef]
- Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2, 795–803. [Google Scholar] [CrossRef]
- Sherman, J.H.; Kirzner, J.; Siu, A.; Amos, S.; Hussainic, I. Sorafenib tosylate as a radiosensitizer in malignant astrocytoma. J. Clin. Neurosci. 2014, 21, 131–136. [Google Scholar] [CrossRef] [PubMed]
- Porta, C.; Paglino, C.; Imarisio, I.; Ferraris, E. Sorafenib tosylate in advanced kidney cancer: Past, present and future. Anti-Cancer Drugs 2009, 20, 409–415. [Google Scholar] [CrossRef]
- Ravikumar, K.; Sridhar, B.; Bhujanga, R.A.K.S.; Reddy, P.M. Sorafenib and its tosylate salt: A multikinase inhibitor for treating cancer. Acta Crystallogr. C 2011, 67, o29–o32. [Google Scholar] [CrossRef]
- Abraham, M.H. Hydrogen bonding. 31. Construction of a scale of solute effective or summation hydrogen-bond basicity. J. Phys. Org. Chem. 1993, 6, 660–684. [Google Scholar] [CrossRef]
- Marcus, Y. The properties of organic liquids that are relevant to their use as solvating solvents. Chem. Soc. Rev. 1993, 22, 409–416. [Google Scholar] [CrossRef]
- Gu, C.; Li, H.; Gandi, R.B.; Raghavan, K. Grouping solvents by statistical analysis of solvent property parameters: Implication to polymorph screening. Int. J. Pharm. 2004, 283, 117–125. [Google Scholar] [CrossRef] [PubMed]
- Mckinnon, J.J.; Jayatilaka, D.; Spackman, M.A. Towards quantitative analysis of intermolecular interactions with Hirshfeld surfaces. Chem. Commun. 2007, 37, 3814–3816. [Google Scholar] [CrossRef]
- Spackman, M.A.; Jayatilaka, D. Hirshfeld surface analysis. CrystEngComm 2009, 11, 19–32. [Google Scholar] [CrossRef]
- Hussain, E.; Kumar, R.; Choudhary, M.I.; Yousuf, S. Crystal engineering of naturally occurring seselin to obtain cocrystal with enhanced anti-leishmanial activity, Hirshfeld surface analysis, and computational insight. Cryst. Growth Des. 2018, 18, 4628–4636. [Google Scholar] [CrossRef]
- Turner, M.J.; McKinnon, J.J.; Wolff, S.K.; Grimwood, D.J.; Spackman, P.R.; Jayatilaka, D.; Spackman, M.A. CrystalExplorer model energies and energy frameworks: Extension to metal coordination compounds, organic salts, solvates and open-shell systems. IUCrJ 2017, 4, 547–587. [Google Scholar]
- Jia, L.; Yu, Y.; Wang, M.; Ouyang, H.; Gong, J. Preparation and characterization for multicomponent crystals of the antidiabetic drug gliquidone based on crystal engineering. CrystEngComm 2019, 21, 1617–1625. [Google Scholar] [CrossRef]
- An, X.; Shen, S.; Wang, W. The preparation methods and properties of the polymorphs of sorafenib tosylate solvates. CN103896833A, 27 December 2012. [Google Scholar]
- Qu, H.; Louhi-Kultanen, M.; Rantanen, J.; Kallas, J. Solvent-mediated phase transformation kinetics of an anhydrate/hydrate system. Cryst. Growth Des. 2006, 6, 2053–2060. [Google Scholar] [CrossRef]
- Wang, X.; Wu, S.; Dong, W.; Gong, J. In situ monitoring of the solvent-mediated transformation of cefadroxil DMF solvate into monohydrate. Org. Process Res. Dev. 2013, 17, 1110–1116. [Google Scholar] [CrossRef]
- Grunenberg, A.; Lenz, J. Thermodynamically stable form of a tosylate salt. PCT WO2006/034797, 6 April 2006. [Google Scholar]
- Scarpitta, F.; Biljan, T. A process for the preparation of solid state forms of sorafenib besylate. PCT WO2012/071425, 31 May 2012. [Google Scholar]
Solvent | Σα | Σβ | π* | Form |
---|---|---|---|---|
methanol | 0.43 | 0.47 | 0.60 | YES |
ethanol | 0.37 | 0.48 | 0.54 | YES |
n-propanol | 0.37 | 0.48 | 0.52 | NO |
isopropanol | 0.33 | 0.56 | 0.48 | NO |
n-butanol | 0.37 | 0.48 | 0.47 | NO |
2-butanol | 0.33 | 0.56 | 0.40 | NO |
isobutanol | 0.37 | 0.48 | 0.40 | NO |
ethyl acetate | 0.00 | 0.48 | 0.55 | NO |
acetone | 0.04 | 0.49 | 0.71 | NO |
acetonitrile | 0.07 | 0.32 | 0.75 | NO |
n-hexane | 0.00 | 0.00 | -0.04 | NO |
cyclohexane | 0.00 | 0.00 | 0.00 | NO |
dichloromethane | 0.10 | 0.05 | 0.82 | NO |
toluene | 0.00 | 0.14 | 0.54 | NO |
NMP | 0.00 | 0.77 | 0.92 | YES |
Parameter | SMe | SEt | SNMP |
---|---|---|---|
Formula | C29H28ClF3N4O7S | C30H30ClF3N4O7S | C38H42ClF3N6O8S |
Formula weight | 669.06 | 683.09 | 835.29 |
Crystal system | monoclinic | monoclinic | triclinic |
Space group | P21/m | P21/m | |
Temperature/K | 293(2) | 293(2) | 293(2) |
Wavelength/Å | 0.71073 | 0.71073 | 0.71073 |
a/Å | 11.684(2) | 11.745(2) | 9.1884(18) |
b/Å | 19.405(4) | 19.412(4) | 10.565(2) |
c/Å | 14.564(3) | 14.650(3) | 21.769(4) |
α/º | 90.000 | 90.000 | 87.27(3) |
β/º | 111.53(3) | 110.57(3) | 81.17(3) |
γ/º | 90.000 | 90.000 | 82.21(3) |
Volume/ų | 3071.7(11) | 3127.1(11) | 2068.2(7) |
Z | 4 | 4 | 2 |
θ range/° | 3.01–25.50 | 3.08–25.50 | 3.07–25.50 |
−14 ≤ h ≤ 14 | −14 ≤ h ≤ 14 | −11 ≤ h ≤ 11 | |
Index ranges | −23 ≤ k ≤ 23 | −22 ≤ k ≤ 23 | −12 ≤ k ≤ 12 |
−16 ≤ l ≤ 17 | −17 ≤ l≤ 17 | −26 ≤ l ≤ 26 | |
Density/g·cm−3 | 1.447 | 1.451 | 1.341 |
Rint | 0.0909 | 0.0657 | 0.0477 |
R1[I>2σ(I)] | 0.0567 | 0.0577 | 0.0708 |
wR2 | 0.1575 | 0.1718 | 0.2584 |
Goodness-of-fit | 1.024 | 1.015 | 1.017 |
CCDC No. | 1505023 | 1505022 | 1505021 |
Solvate | D−H···A | d(D−H)/Å | d(H···A)/Å | d(D···A)/Å | ∠(DHA)/° |
---|---|---|---|---|---|
SMea | N(1)-H(1A)···O(4) | 0.86 | 2.06 | 2.895 | 162.3 |
N(2)-H(2A)···O(4) | 0.86 | 2.26 | 3.064 | 155.0 | |
SEtb | N(1)-H(1A)···O(5) | 0.86 | 2.06 | 2.892 | 163.0 |
O(7)-H(7A)···O(6) | 0.82 | 2.02 | 2.771 | 151.5 | |
SNMPc | N(1)-H(1A)···O(5) | 0.86 | 2.07 | 2.823(4) | 146.0 |
Solvate | SMe | SEt | SNMP |
---|---|---|---|
Solvent | Methanol | Ethanol | N-methyl-2-pyrrolidone |
Stoichiometry | 1:1 | 1:1 | 1:2 |
Theoretical weight loss/% | 4.8 | 6.7 | 23.7 |
Experimental weight loss/% | 4.6 | 7.0 | 24.0 |
Desolvation onset Ton/℃ | 102 | 98 | 106 |
Desolvation product | Form I | Form I | Form I |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yang, P.; Qin, C.; Du, S.; Jia, L.; Qin, Y.; Gong, J.; Wu, S. Crystal Structure, Stability and Desolvation of the Solvates of Sorafenib Tosylate. Crystals 2019, 9, 367. https://doi.org/10.3390/cryst9070367
Yang P, Qin C, Du S, Jia L, Qin Y, Gong J, Wu S. Crystal Structure, Stability and Desolvation of the Solvates of Sorafenib Tosylate. Crystals. 2019; 9(7):367. https://doi.org/10.3390/cryst9070367
Chicago/Turabian StyleYang, Peng, Chunlei Qin, Shichao Du, Lina Jia, Yujia Qin, Junbo Gong, and Songgu Wu. 2019. "Crystal Structure, Stability and Desolvation of the Solvates of Sorafenib Tosylate" Crystals 9, no. 7: 367. https://doi.org/10.3390/cryst9070367
APA StyleYang, P., Qin, C., Du, S., Jia, L., Qin, Y., Gong, J., & Wu, S. (2019). Crystal Structure, Stability and Desolvation of the Solvates of Sorafenib Tosylate. Crystals, 9(7), 367. https://doi.org/10.3390/cryst9070367